Superscan Articles

Actinium-225-labeled prostate-specific membrane antigen ([225Ac]Ac-PSMA-617) is safe and effective in the treatment of metastatic castration-resistant prostate cancer (mCRPC). No study has specifically assessed its safety in patients with extensive skeletal metastases of mCRPC.

A 74-year-old man presented to the Andrology Clinic for management of potential complications of androgen deprivation therapy for prostate cancer. He had a rising prostate-specific antigen with a concurrent rise in alkaline phosphatase and bone remodeling markers.

Excessive skeletal radioisotope uptake in relation to soft tissues along with absent or faint activity in the genitourinary tract on skeletal scintigraphy is known as a "superscan." Prostate cancer is the most common cause of superscan in skeletal scintigraphy due to diffuse skeletal metastases.